Articles & Press Releases

Rare Disease Therapies and the Case for Outcomes-Based Agreements

Treatments for rare diseases, such as spinal muscular atrophy or CAR-T therapies like tisagenlecleucel, hold transformative potential for patients. Yet, they often come with significant challenges—uncertainties around long-term efficacy, high costs, and the need for tailored patient selection. Outcomes-Based Agreements (OBAs) offer a structured way to address these challenges, aligning financial risk with therapeutic outcomes. However, their implementation requires careful consideration and planning.

The Shift to Financially Optimized Clinical Trials

As value-based contracting (VBCs) becomes the standard, the role of clinical trials has shifted significantly. They are now essential not only for demonstrating safety and efficacy but also for enhancing financial performance. By creating trials that meet the criteria of VBCs, pharmaceutical companies can increase their financial gains, minimize pricing risks, and facilitate smoother negotiations with payers.

Clinical Trial Outcomes: The Key to Driving Drug Pricing and Market Access

In value-based contracts (VBCs), clinical trial outcomes are no longer just about proving safety and efficacy—they’re now critical to driving drug pricing and market access strategies. As payers and healthcare systems shift towards outcome-based models, trial data is becoming the foundation for negotiating both price and reimbursement.

UK: Standardizing the economic evaluation of AI tech

Introduction

Spain: Reducing unnecessary care and improving HTA education

Introduction

Lyfegen and EVERSANA Collaborate to Revolutionize Drug Pricing and Access with AI-Driven Insights

Basel, Switzerland –28, January 2025 - Lyfegen, a global innovator in drug market access, pricing, and rebate management, has announced a transformative collaboration with EVERSANA®, a leading provider of global commercial services to the life sciences industry, to revolutionize drug pricing and access through artificial intelligence-driven insights.

Lyfegen Secures additional CHF 5 Million in Series A Funding to Scale Its Drug Rebate Management Platform Globally

Basel, Switzerland / Boston, USA – December 11, 2024

A New Era in Canadian Healthcare: Lyfegen's CEO Discusses Groundbreaking Collaboration

In an industry often characterized by incremental changes, Girisha Fernando, the CEO and founder of Lyfegen, is making leaps. We sat down with Fernando to discuss the recent landmark partnership between Lyfegen and Newfoundland and Labrador Health Services—a collaboration that heralds a significant shift in the Canadian healthcare landscape.

Swiss health insurance Sympany implements Lyfegen Platform to efficiently execute complex value & data-driven agreements for high-priced medication.

Lyfegen Launches the World's Largest Database of Value-Based Drug Agreements

New York, NY - March 29, 2023 - Lyfegen, a global healthtech SaaS company driving the world’s transition from volume to value-based healthcare for high-cost drugs, announced at the World EPA Congress the launch of its latest solution: the Model & Agreement Library. The purpose of the library is to help payers and pharma negotiate better drug prices while providing an in-depth view on current international drug pricing models and value-based agreements. The database library serves as the basis for successful drug pricing negotiations, resulting in accelerated access and drug prices better aligned to their value for the patient.

Transforming Healthcare Access in Canada: Ina Hasani’s Vision at Lyfegen

We are thrilled to welcome Ina Hasani to our team at Lyfegen as Director of Sales & Business Development for Canada. Ina brings nearly a decade of experience in the life sciences sector, specializing in healthcare strategy, market access, and health economics. We sat down with Ina to learn more about her background, her vision for transforming healthcare in Canada, and what excites her most about joining Lyfegen.

A Fable of the Blue Bird and Lyfegen's Wise Owls

Once upon a time, In a whimsical forest, there lived a smart and creative blue bird. This bird, known for its brilliance in the world of tiny forest biotech, had concocted a magical potion.

Driving Growth: Welcoming Our New VP of Sales & Business Development, Simon Farrow

Amid the buzz of innovation at Lyfegen, we sat down with Simon, our newest team member, whose journey has brought a fresh...

Driving Growth: Welcoming Our New VP of Sales & Business Development, Simon Farrow

Amid the buzz of innovation at Lyfegen, we sat down with Simon, our newest team member, whose journey has brought a fresh perspective to our mission.

Amid the buzz of innovation at Lyfegen, we sat down with Simon, our newest team member, whose journey has brought a fresh...

Exclusive interview with Girisha Fernando at the launch of Lyfegen’s Value-Based Agreement Library

At this years World Evidence, Pricing and Access event, Girisha Fernando, the CEO of Lyfegen, expressed excitement as he spoke about the company’s latest launched offering - the Lyfegen Model & Agreement Library. This unique learning resource is a true game-changer that builds upon the company’s existing product. It expands our horizons by allowing payers and market access & pricing professionals to explore over 2’500 real-life public agreements, and 18 drug pricing models from around the world. The library provides an unparalleled understanding of drug reimbursement models that help users make better informed choices like never before.

The Tech Team Keeps Growing! Welcome to the Lyfegen Team, Analytical-Superstar, Pavlo!

He’s analytical, a techie and has a fantastic gift for music! Yes, we are talking about the latest addition to our team, our very own “Technical Business Analyst” and Ukrainian superstar: Pavlo Lupandin!

Clinical Trial Outcomes: The Key to Driving Drug Pricing and Market Access

UK: Standardizing the economic evaluation of AI tech

Introduction

Spain: Reducing unnecessary care and improving HTA education

Introduction

Switzerland. Improving the fast-track process and anti-migraine drugs

Introduction

FDA Launches a new program to speed patient access

Introduction

All the insights you need in one place.

On-Demand Insights

Rewriting the Playbook: ​ How AI Can Accelerate Market Access & Pricing Decisions​

2024 in Review: Are Drug Access Agreement Trends Going the Right Way?

Revolutionizing Drug Access in Portugal: Scaling Outcome-Based Agreements with Digital Innovation

Innovative Rebate Management in Oncology Drug Budgets

Articles & Press Releases

Rare Disease Therapies and the Case for Outcomes-Based Agreements

Rare Disease Therapies and the Case for Outcomes-Based Agreements

The Shift to Financially Optimized Clinical Trials

The Shift to Financially Optimized Clinical Trials

Clinical Trial Outcomes: The Key to Driving Drug Pricing and Market Access

Clinical Trial Outcomes: The Key to Driving Drug Pricing and Market Access

UK: Standardizing the economic evaluation of AI tech

UK: Standardizing the economic evaluation of AI tech

Spain: Reducing unnecessary care and improving HTA education

Spain: Reducing unnecessary care and improving HTA education

Lyfegen and EVERSANA Collaborate to Revolutionize Drug Pricing and Access with AI-Driven Insights

Lyfegen and EVERSANA Collaborate to Revolutionize Drug Pricing and Access with AI-Driven Insights

Lyfegen Secures additional CHF 5 Million in Series A Funding to Scale Its Drug Rebate Management Platform Globally

Lyfegen Secures additional CHF 5 Million in Series A Funding to Scale Its Drug Rebate Management Platform Globally

A New Era in Canadian Healthcare: Lyfegen's CEO Discusses Groundbreaking Collaboration

A New Era in Canadian Healthcare: Lyfegen's CEO Discusses Groundbreaking Collaboration

Swiss health insurance Sympany implements Lyfegen Platform to efficiently execute complex value & data-driven agreements for high-priced medication.

Swiss health insurance Sympany implements Lyfegen Platform to efficiently execute complex value & data-driven agreements for high-priced medication.

Lyfegen Launches the World's Largest Database of Value-Based Drug Agreements

Lyfegen Launches the World's Largest Database of Value-Based Drug Agreements

Transforming Healthcare Access in Canada: Ina Hasani’s Vision at Lyfegen

Transforming Healthcare Access in Canada: Ina Hasani’s Vision at Lyfegen

A Fable of the Blue Bird and Lyfegen's Wise Owls

A Fable of the Blue Bird and Lyfegen's Wise Owls

Driving Growth: Welcoming Our New VP of Sales & Business Development, Simon Farrow

Driving Growth: Welcoming Our New VP of Sales & Business Development, Simon Farrow

Exclusive interview with Girisha Fernando at the launch of Lyfegen’s Value-Based Agreement Library

Exclusive interview with Girisha Fernando at the launch of Lyfegen’s Value-Based Agreement Library

The Tech Team Keeps Growing! Welcome to the Lyfegen Team, Analytical-Superstar, Pavlo!

The Tech Team Keeps Growing! Welcome to the Lyfegen Team, Analytical-Superstar, Pavlo!

Clinical Trial Outcomes: The Key to Driving Drug Pricing and Market Access

Clinical Trial Outcomes: The Key to Driving Drug Pricing and Market Access

UK: Standardizing the economic evaluation of AI tech

UK: Standardizing the economic evaluation of AI tech

Spain: Reducing unnecessary care and improving HTA education

Spain: Reducing unnecessary care and improving HTA education

Switzerland. Improving the fast-track process and anti-migraine drugs

Switzerland. Improving the fast-track process and anti-migraine drugs

FDA Launches a new program to speed patient access

FDA Launches a new program to speed patient access

Rewriting the Playbook: How AI Can Accelerate Market Access & Pricing Decisions